This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 1993 Oct;12(5):583-9.

doi: 10.1089/hyb.1993.12.583.

Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13

R P Baum¹, A A Noujaim, A Nanci, V Moebus, A Hertel, A Niesen, B Donnerstag, T Sykes, G Boniface, G Hör

Affiliations

PMID: 8300134
DOI: 10.1089/hyb.1993.12.583

Case Reports

Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13

R P Baum et al. Hybridoma. 1993 Oct.

. 1993 Oct;12(5):583-9.

doi: 10.1089/hyb.1993.12.583.

Authors

R P Baum¹, A A Noujaim, A Nanci, V Moebus, A Hertel, A Niesen, B Donnerstag, T Sykes, G Boniface, G Hör

Affiliation

¹ Department of Nuclear Medicine, University of Frankfurt, Germany.

PMID: 8300134
DOI: 10.1089/hyb.1993.12.583

No abstract available

PubMed Disclaimer

Similar articles

Influence of human anti-murine antibodies on in vitro assays in ovarian cancer patients.
Hertel A, Baum R. Hertel A, et al. Hybridoma. 1993 Oct;12(5):571-6. doi: 10.1089/hyb.1993.12.571. Hybridoma. 1993. PMID: 8300132 No abstract available.
Are human anti-idiotypic anti-OC125 antibodies formed after immunization with the anti-CA125 antibody B43.13?
Reinsberg J, Krebs D. Reinsberg J, et al. Hybridoma. 1997 Feb;16(1):59-63. doi: 10.1089/hyb.1997.16.59. Hybridoma. 1997. PMID: 9085130
Idiotypic cascades after MAb OC125 application.
Reinsberg J. Reinsberg J. Hybridoma. 1993 Oct;12(5):577-82. doi: 10.1089/hyb.1993.12.577. Hybridoma. 1993. PMID: 8300133 No abstract available.
[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U, Köhler S, Prietl G, Giffels P, Schmidt-Nicolai S, Schlebusch H, Grünn U, Bender H, Biersack HJ, De Potter C, Krebs D, Wallwiener D. Wagner U, et al. Zentralbl Gynakol. 1999;121(4):190-5. Zentralbl Gynakol. 1999. PMID: 10355096 Review. German.
Ovarian carcinoma therapy with monoclonal antibodies.
Canevari S, Miotti S, Bottero F, Valota O, Colnaghi MI. Canevari S, et al. Hybridoma. 1993 Oct;12(5):501-7. doi: 10.1089/hyb.1993.12.501. Hybridoma. 1993. PMID: 8300122 Review. No abstract available.

See all similar articles

Cited by

Monoclonal antibodies in gynecological cancer: a critical point of view.
Bellati F, Napoletano C, Gasparri ML, Visconti V, Zizzari IG, Ruscito I, Caccetta J, Rughetti A, Benedetti-Panici P, Nuti M. Bellati F, et al. Clin Dev Immunol. 2011;2011:890758. doi: 10.1155/2011/890758. Epub 2011 Dec 26. Clin Dev Immunol. 2011. PMID: 22235224 Free PMC article. Review.
Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
Buzzonetti A, Fossati M, Catzola V, Scambia G, Fattorossi A, Battaglia A. Buzzonetti A, et al. Cancer Immunol Immunother. 2014 Oct;63(10):1037-45. doi: 10.1007/s00262-014-1569-0. Epub 2014 Jun 21. Cancer Immunol Immunother. 2014. PMID: 24952307 Free PMC article. Clinical Trial.
Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.
Grisham RN, Berek J, Pfisterer J, Sabbatini P. Grisham RN, et al. Immunotherapy. 2011 Feb;3(2):153-62. doi: 10.2217/imt.10.100. Immunotherapy. 2011. PMID: 21322756 Free PMC article. Review.
Immuno-PET of epithelial ovarian cancer: harnessing the potential of CA125 for non-invasive imaging.
Sharma SK, Wuest M, Wang M, Glubrecht D, Andrais B, Lapi SE, Wuest F. Sharma SK, et al. EJNMMI Res. 2014 Dec;4(1):60. doi: 10.1186/s13550-014-0060-4. Epub 2014 Nov 12. EJNMMI Res. 2014. PMID: 26116121 Free PMC article.
Mucin-Targeted Antibodies for Ovarian Cancer.
Lawson SA, Lewis JS. Lawson SA, et al. Semin Nucl Med. 2025 Jul 3:S0001-2998(25)00071-6. doi: 10.1053/j.semnuclmed.2025.06.007. Online ahead of print. Semin Nucl Med. 2025. PMID: 40615275 Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information